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Serum samples from children immunized with a meningo-
coccal serogroup B vaccine demonstrated potent serum 
bactericidal antibody activity against the hypervirulent Neis-
seria meningitidis serogroup W strain circulating in England. 
The	recent	introduction	of	this	vaccine	into	the	United	King-
dom national immunization program should also help pro-
tect infants against this endemic strain.
Invasive meningococcal disease (IMD) has been declin-ing in the United Kingdom since the early 2000s (1). His-
torically, serogroup W Neisseria meningitides meningo-
cocci (MenW) have been causal organisms for 1%–2% of 
IMD cases annually. An increase in invasive MenW disease 
associated with travel to the Hajj pilgrimage route during 
2000–2002 was rapidly controlled after the introduction of 
mandatory vaccination for pilgrims (2). Since 2009, how-
ever, laboratory-confirmed MenW cases in England have 
increased each year across all age groups after rapid spread 
of a single endemic hypervirulent sequence type (ST) 11 
clonal complex (MenW:cc11) strain (3). This strain has 
caused severe illness with unusual clinical manifestations 
and, for the first time in more than a decade, was associated 
with fatal outcomes among infants and young children.
Since the Hajj outbreak, several countries in Latin 
America, Africa, and the Far East have reported an increase 
in MenW disease and ongoing endemic transmission (3). 
In Chile, MenW has replaced serogroup B (MenB) as the 
most prevalent cause of IMD, identified in 58% of cases in 
2012 (4). In Europe, an increase in MenW disease has not 
been observed in other countries although, in 2012, a clus-
ter of cases related to MenW:cc11 in France was associated 
with travel to sub-Saharan Africa (5).
In England, the meningococcal quadrivalent conju-
gate vaccine (MenACWY, covering serogroups A, C, W, 
and Y) has historically been recommended for high-risk 
persons and travelers to disease-endemic regions and for 
controlling outbreaks (6). Beginning on September 1, 
2015, a novel, protein-based, multicomponent vaccine, 
Bexsero (GSK Vaccines, Siena, Italy), has been offered 
as part of the routine immunization program in the United 
Kingdom; the vaccine is given to infants in 3 doses at 2, 4, 
and 12 months of age (https://www.gov.uk/government/
publications/menb-vaccination-introduction-from-1-sep-
tember-2015). Bexsero is composed of NHBA (neisserial 
heparin binding antigen), NadA (Neisseria adhesin A) 
and fHbp (factor H binding protein), with meningococ-
cal outer membrane vesicles from an MenB strain from 
an outbreak in New Zealand (7). Immunization with Bex-
sero induces bactericidal antibodies against all vaccine 
antigens (8). Although this vaccine has been licensed for 
prevention of MenB disease (the most prevalent capsu-
lar group causing IMD in Europe), alleles for some or all 
of the vaccine antigens are also found among non-MenB 
meningococci, independently of the capsule. Therefore, 
antibodies raised by these antigens could induce comple-
ment-mediated killing of other meningococcal groups, in-
cluding the endemic MenW cc11 strain. 
Recently, we reported the predominance of non–
cross-protective PorA (P1.5,2) and fHbp variants (variant 
2 peptide 22) among endemic MenW:cc11 isolates (3). 
The other primary Bexsero antigens (NadA and NHBA), 
however, could potentially afford protection. We there-
fore assessed 1) the NadA and NHBA genotypic status of 
endemic MenW:cc11 isolates, and 2) the serum bacteri-
cidal antibody (SBA) activity against clinical MenW:cc11 
isolates using serum samples from infants immunized 
with Bexsero.
The Study
A total of 73 invasive MenW:cc11 isolates from England 
and Wales were received by the Public Health England Me-
ningococcal Reference Unit during July 2010–June 2013. 
These isolates were queried within the Meningitis Research 
Foundation Meningococcus Genome Library (http://
pubmlst.org/perl/bigsdb/bigsdb.pl?db = pubmlst_neisse-
ria_mrfgenomes) for nadA and nhba and, where present, 
their respective allelic and peptide variants.
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DISPATCHES
We used an SBA using human complement (hSBA) 
against 6 invasive MenW:cc11 isolates from patients 4 
months–91 years of age in whom meningitis or septicemia 
was diagnosed in different regions of England and Wales 
during 2011–2012. SBA titers were expressed as the recipro-
cal of the serum dilution corresponding to >50% bacterial 
killing. We used pooled serum samples from phase 2 clinical 
trials involving infants immunized with Bexsero at 2, 3, and 
4 months or 2, 4, and 6 months and after administration of a 
booster at 12, 18, or 24 months (8). Pooled prevaccination 
serum samples from 180 infants were used as negative con-
trols, and pooled serum samples from 10 randomly selected 
adolescents who received a single MenACWY conjugate 
vaccine (GSK Vaccines) dose as positive controls.
Of the 6 isolates tested, 4 possessed nadA allele 5 (for 
peptide NadA-2/3.6) and nhba allele 17 (for NHBA peptide 
29). Of the remaining 2 isolates, 1 isolate had a nadA allele 
(allele 146) that differed at a single nucleotide (C476A), 
causing a single amino acid change (T159K; peptide 
NadA-2/3.130); the other isolate had an nhba allele (allele 
72) that differed at a single nucleotide (A376C), causing a 
single amino acid change (T126P; peptide 96).
hSBA titers were high and were >1:32 against all 6 
MenW isolates, independently of the immunization sched-
ule (Table). After the booster, higher hSBA titers were ob-
tained than those from primary immunization, and similar 
responses were comparable to those among adolescents 
who had received a single MenACWY dose. Preimmuni-
zation serum samples showed no detectable hSBA titers 
against any of the 6 isolates (Table).
Conclusions
The ability of the antibodies raised by Bexsero antigens 
to induce SBA activity against any given meningococcal 
isolate depends on the presence, level of surface expres-
sion, and sequence diversity of the respective antigens. 
Bexsero strain coverage can be predicted by using the 
Meningococcal Antigen Typing System, an ELISA which 
measures the level of antigen expression and antigenic di-
versity compared with the antigen in the vaccine (9). How-
ever, the correlation between the relative potency estimated 
by this typing system and the ability of a meningococcal 
isolate to be killed by serum from immunized persons has 
only been defined for MenB strains. 
We found that MenW:cc11 isolates causing invasive 
disease in England and Wales possessed alleles for NadA-
2/3 peptide variants that are predicted to be highly cross-pro-
tective with the Bexsero NadA variant (10). The isolates also 
possessed alleles for NHBA peptide 29 which, although dif-
ferent from peptide 2 in Bexsero, has the potential to induce 
cross-protection even if NHBA-containing cross-protective 
epitopes have not been defined yet. Antibodies against 
Bexsero antigens can act synergistically and, therefore, the 
complement-mediated bactericidal killing observed could be 
mediated by antibodies against NadA, NHBA, or both.
In England, the ongoing MenW increase is similar 
to the MenC:cc11 outbreak in the mid-1990s, which was 
eventually controlled through mass vaccination (11). The 
increase in MenW cases has led to the rapid introduction 
of a national adolescent MenACWY conjugate vaccination 
program in August 2015 (https://www.gov.uk/government/
news/new-meningococcal-vaccination-programme-ex-
pected-to-save-lives). In adolescents, a single MenACWY 
dose would provide direct protection and, by targeting the 
age group most likely to carry meningococci (12), could 
also provide indirect protection against MenW (Figure) 
and the other 3 capsular groups by reducing carriage and 
onward transmission to others.
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Table. Bactericidal antibody titers in pooled serum samples from	infants	vaccinated	with	Bexsero	and	adolescents	immunized	with	
Menveo	against	6	invasive	clinical	Neisseria meningitidis serogroup	W	isolates	in	England	and	Wales,	UK,	during	2011–2012* 
Isolate 
Adolescents receiving Menveo 
 
Infants	receiving	Bexsero 
Positive control† Negative	
control‡ Pool	1§ Pool	2¶ Pool 3# Pool	4** Before After 
M11–240417 <16 256  <2 64 128 >128 >128 
M11–240427 <16 128  <2 32 32 64 64 
M11–240802 <16 512  <2 32 >64 >64 >64 
M12–240016 <16 256  <2 32 32 64 128 
M11–240798 <16 512  <2 >64 >64 >64 >64 
M12–240754 <16 256  <2 64 64 >64 >64 
*Human	serum	bactericidal	antibody	titers	against	6	meningococcal	group	W	clinical	isolates	belonging	to	ST-11	clonal	complex	using	
pooled	serum	from	adolescents	immunized	with	the	MenACWY	conjugate	vaccine,	Menveo,	and	from	infants	immunized	with	the	protein-
based, multicomponent meningococcal vaccine,	Bexsero. 
†Pooled serum samples from adolescents 11–17	years	of	age	before	and	1	month	after	receiving	a	single	dose	of	MenACWY	(Menveo)	
conjugate	vaccine	(n	=	10). 
‡Pooled prevaccination serum samples from infants at 2 months of age (n = 180) (control). 
§Pooled	serum	samples	from	infants	who	received	3	doses	of	vaccine	at	2,	3,	and	4	months	of	age	and	had	a	blood	sample	taken	1	
month	after	the	last	dose	of	vaccine	(n	=	56). 
¶Pooled	serum	samples	from	infants	who	received	3	doses	of	vaccine	at	2,	4,	and	6	months	of	age	and	had	a	blood	sample	taken	1	
month	after	the	last	dose	of	vaccine	(n	=	47). 
#Pooled	serum	samples	from	infants	who	received	3	doses	of	vaccine	at	2,	4,	and	6	months	of	age	plus	a	booster	at	12	months	and had 
a	blood	sample	taken	1	month	after	the	booster	(n	=	72). 
**Pooled	serum	samples	from	an	additional	cohort	of	infants	who	also	received	3	doses	of	vaccine	at	2,	4,	and	6	months	of	age plus a 
booster	at	12	months	and	had	a	blood	sample	taken	1	month	after	the	booster	(n	=	94). 
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Conversely, infants would require >2 MenACWY dos-
es starting at 2 months of age, because MenW cases increase 
from birth and peak at 7 months of age before declining. 
Bexsero, which is predicted to protect against 73%–88% of 
invasive MenB isolates in England and Wales (9,13), could 
offer additional protection against MenB, which causes more 
cases among infants and toddlers than the other meningococ-
cal serogroups. Among infants (<1 year of age), 101 MenB 
cases were reported during 2014–2015, compared with 21 
MenW, 4 MenY, and 1 MenC; among toddlers, (1–4 years 
of age), 139 MenB cases were reported, compared with 18 
MenW, 5 MenY, and 0 MenC. The difference in adolescents 
(15–19 years of age) is less pronounced, but 36 MenB cases 
were reported in this age group during 2014–2015, com-
pared with 25 MenW, 14 MenY and 3 MenC cases (https://
www.gov.uk/government/uploads/system/uploads/attach-
ment_data/file/476989/hpr38-3915.pdf). However, the ef-
fectiveness of Bexsero against meningococcal carriage and, 
therefore, its ability to provide herd protection, which is a 
major objective of an adolescent programme, is less certain 
than with conjugate vaccines (14). These observations and 
our results support the recent implementation of both the 
adolescent MenACWY conjugate and infant MenB immu-
nization programmes in the UK.
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Figure.	Age	distribution	of	all	laboratory-confirmed,	invasive	
Neisseria meningitidis	serogroup	W	disease	cases	identified	in	
England	during	July	2009–December	2014.
